44. Wegener granulomatosis Clinical trials / Disease details


Clinical trials : 92 Drugs : 106 - (DrugBank : 27) / Drug target genes : 22 - Drug target pathways : 78

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04316494
(ClinicalTrials.gov)
December 17, 202025/2/2020Hydroxychloroquine in ANCA Vasculitis EvaluationHydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled TrialANCA Associated Vasculitis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Wegener GranulomatosisDrug: Hydroxychloroquine;Drug: PlaceboGuy's and St Thomas' NHS Foundation TrustMedical Research CouncilRecruiting18 YearsN/AAll76Phase 4United Kingdom
2EUCTR2018-001268-40-GB
(EUCTR)
23/01/202013/09/2019Hydroxychloroquine in ANCA vasculitisHydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVEN The term ANCA-associated vasculitis (AAV) describes a subset of primary small vessel vasculitides characterized by the presence of anti-neutrophil cytoplasmic antibodies (ANCA): Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA). AAV are serious multisystem autoimmune disorders that can affect any organ in the body and commonly involve the ear-nose-throat, lungs, kidneys, eyes and joints
MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: Plaquenil - Hydroxychloroquine 200mg Film coated tabletsGuy's and St. Thomas' NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
76Phase 4United Kingdom